naratriptan hydrochoride

PreclinicalSmall molecule

RRoxane Laboratories

naratriptan hydrochoride is one of 46 small molecule programs targeting TED. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TEDCompleted

FedCompleted

TEDPreclinical

Completed

FedPreclinical

Completed

Competition

Competitive Landscape

45 competitors in TED

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Approved

2 2

Alecensa

Roche

Approved

1 3

Scemblix

Novartis

Approved

1 4

Medrol

Pfizer

Phase 3

2 5

Rituxan

Roche

Phase 3

2 6

Calquence

AstraZeneca

Phase 3

2 7

Golytely

Bayer

Phase 3

1 8

Treanda

AAzurity Pharmaceuticals

Phase 3

1 9

Fludara

Sanofi

Phase 2

3 10

Eliquis

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

TED1 trial

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions

Completed·RRoxane Laboratories·N/A·NCT01161667·35 enrolled

Fed1 trial

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT01161654·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for naratriptan hydrochoride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — naratriptan hydrochoride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for naratriptan hydrochoride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roxane Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRoxane Laboratories

naratriptan hydrochoride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

TED1 trial

Fed1 trial

References

Drug Info

Quick Facts

Related News